Evidence map›Paper›PMID 27665165›Full record

ArticleJACC. Cardiovascular imaging2017

Early Gadolinium Enhancement for Determination of Area at Risk: A Preclinical Validation Study.

Sophia Hammer-Hansen, Steve W Leung, Li-Yueh Hsu, Joel R Wilson, Joni Taylor, Anders M Greve, Jens Jakob Thune, Lars Køber, Peter Kellman, Andrew E Arai

Open access · greenAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Cardiovascular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Molecular Imaging in Ischemic Heart Disease.Current cardiovascular imaging reports · 2019
    Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Sophia Hammer-HansenLaboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; Department of Medicine B, The Heart Center, Rigshospitalet, Copenhagen, Denmark.
Steve W LeungLaboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; Department of Medicine and Radiology, Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky.
Li-Yueh HsuLaboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
Joel R WilsonLaboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; Department of Medicine and Radiology, Division of Cardiovascular Medicine, University of California-San Diego, San Diego, California.
Joni TaylorLaboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
Anders M GreveLaboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
Jens Jakob ThuneDepartment of Medicine B, The Heart Center, Rigshospitalet, Copenhagen, Denmark.
Lars KøberDepartment of Medicine B, The Heart Center, Rigshospitalet, Copenhagen, Denmark.
Peter KellmanLaboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
Andrew E AraiLaboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. Electronic address: araia@nih.gov.
National Heart Lung and Blood Institute · USNational Institutes of Health · USRigshospitalet · DK

Funding

Technical Development of Diagnostic Cardiovascular MRIZIAHL004607 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ARAI, ANDREW · 2009 to 2020
$25.3M
Advanced Cardiovascular Imaging FellowshipZIEHL006139 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ARAI, ANDREW · 2011 to 2020
$8.8M
MRI Evaluation Of Acute Cardiovascular DiseaseZ01HL004607 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ARAI, ANDREW E · 1999 to 2008
$8.0M
Area at Risk, Myocardial Infarction, and Myocardial SalvageZIAHL006136 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ARAI, ANDREW · 2011 to 2020
$7.3M
Intramural NIH HHS Z01 HL004607Intramural NIH HHS ZIA HL004607Intramural NIH HHS ZIA HL006136
6 · The paper itself

Abstract

objectivesThe aim of this study was to determine whether early gadolinium enhancement (EGE) by cardiac magnetic resonance (CMR) in a canine model of reperfused myocardial infarction depicts the area at risk (AAR) as determined by microsphere blood flow analysis.

backgroundIt remains controversial whether only the irreversibly injured myocardium enhances when CMR is performed in the setting of acute myocardial infarction. Recently, EGE has been proposed as a measure of the AAR in acute myocardial infarction because it correlates well with T2-weighted imaging of the AAR, but this still requires pathological validation.

methodsEleven dogs underwent 2 h of coronary artery occlusion and 48 h of reperfusion before imaging at 1.5-T. EGE imaging was performed 3 min after contrast administration with coverage of the entire left ventricle. Late gadolinium enhancement imaging was performed between 10 and 15 min after contrast injection. AAR was defined as myocardium with blood flow <2 SD from remote myocardium determined by microspheres during occlusion. The size of infarction was determined with triphenyltetrazolium chloride.

resultsThere was no significant difference in the size of enhancement by EGE compared with the size of AAR by microspheres (44.1 ± 15.8% vs. 42.7 ± 9.2%; p = 0.61), with good correlation (r = 0.88; p < 0.001) and good agreement by Bland-Altman analysis (mean bias 1.4 ± 17.4%). There was no difference in the size of enhancement by EGE compared with enhancement on native T1 and T2 maps. The size of EGE was significantly greater than the infarct by triphenyltetrazolium chloride (44.1 ± 15.8% vs. 20.7 ± 14.4%; p < 0.001) and late gadolinium enhancement (44.1 ± 15.8% vs. 23.5 ± 12.7%; p < 0.001).

conclusionsAt 3 min post-contrast, EGE correlated well with the AAR by microspheres and CMR and was greater than infarct size. Thus, EGE enhances both reversibly and irreversibly injured myocardium.

Indexed as

Coronary CirculationAnimalsBlood Flow VelocityContrast MediaDisease Models, AnimalDogsFluorescent DyesGadolinium DTPAMagnetic Resonance ImagingMicrospheresMyocardial InfarctionMyocardial Perfusion ImagingMyocardial Reperfusion InjuryMyocardiumPredictive Value of TestsTime FactorsContrast MediaFluorescent DyesGadolinium DTPAacute myocardial infarctionarea at riskcardiac magnetic resonancegadolinium enhancement

Identifiers

PMID27665165
PMCPMC5384795
OpenAlexW2538498324

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.